All Experimentica sites are now CIR-accredited
Experimentica’s sites have gained CIR accreditation for 2026-2028, enabling eligible French companies to benefit from CIR-covered preclinical ophthalmic research services.
Learn moreExperimentica’s sites have gained CIR accreditation for 2026-2028, enabling eligible French companies to benefit from CIR-covered preclinical ophthalmic research services.
Learn moreResearchers at Experimentica have demonstrated that human induced pluripotent stem cell-derived retinal pigment epithelium (hiPSC-RPE) cells provide a highly relevant in vitro model for studying oxidative stress-related retinal diseases, including age-related macular degeneration (AMD). The study showed that these cells closely resemble native human RPE tissue both morphologically and functionally, making them a valuable platform for preclinical research and drug development.
Learn moreHeading to Boston or based in the area? Let’s connect! Whether you’re attending LSX or are simply in the Boston area, our Business Development team would be happy to meet and discuss your ophthalmic drug development needs.
Learn moreExperimentica has appointed Dr. Marc Cerrada-Gimenez as Director, In Vivo GLP Operations, supporting the expansion of its GLP safety and toxicology capabilities in Kuopio, Finland.
Learn moreFinnish animal welfare legislation (Government Decree 1165/2023) effective as of January 1, 2024, requires establishments to apply “appropriate pain relief” in association with ear notching identification method of laboratory rodents(1). However, there is a lack of scientific evidence whether the benefits of applying analgesia outweigh the additional stress related to handling and drug administration. Our study aimed to determine if acute pain potentially linked to ear notching increases self-grooming behavior of the affected body area and if topical application of lidocaine-prilocaine ointment has the potential to mitigate such pain.
Learn moreOcular uveitis is a major cause of vision loss and often requires corticosteroid therapy to control inflammation. Intravitreal administration of tumor necrosis factor alpha (TNF-α) in rabbit eyes causes ocular inflammation in the anterior chamber, iris hyperemia, and vitreal haze. The purpose of this study was to compare the anti-inflammatory efficacy of intravitreal Ozurdex, systemic prednisolone, and topical dexamethasone.
Learn moreThe objective of this study was to evaluate the level of neurodegeneration and visual functional degradation, as well as the protective effect of fingolimod in a mouse EAE model.
Learn moreIn 2026, we will be attending a range of key events across the globe - and we invite you to meet us in person! Join us to discuss ideas, explore opportunities, and see how we can support you and your team in ocular drug development.
Learn moreExperimentica strengthens its position as a leading global ophthalmic CRO by investing in a new GLP‑compliant facility, enabling comprehensive GLP safety and toxicology studies for innovative ocular therapies.
Learn moreExperimentica Ltd., a trusted partner in preclinical drug development for ocular diseases, is pleased to announce the appointment of Teija Parkkari as Director of Business Development, effective April 13, 2026.
Learn moreCopyright: Experimentica Ltd. 2026